Literature DB >> 15735812

Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction.

Maria Nastase Mannila1, Per Eriksson, Pia Lundman, Ann Samnegård, Susanna Boquist, Carl-Göran Ericsson, Per Tornvall, Anders Hamsten, Angela Silveira.   

Abstract

Fibrinogen has consistently been recognized as an independent predictor of myocardial infarction (MI). Multiple mechanisms link fibrinogen to MI; therefore disentangling the factors underlying variation in plasma fibrinogen concentration is essential. Candidate regions in the fibrinogen gamma (FGG), alpha (FGA) and beta (FGB) genes were screened for single nucleotide polymorphisms (SNPs). Several novel SNPs were detected in the FGG and FGA genes in addition to the previously known SNPs in the fibrinogen genes. Tight linkage disequilibrium extending over various physical distances was observed between most SNPs. Consequently, eight SNPs were chosen and determined in 377 postinfarction patients and 387 healthy individuals. None of the SNPs were associated with plasma fibrinogen concentration or MI. Haplotype analyses revealed a consistent pattern of haplotypes associated with variation in risk of MI. Of the four haplotypes inferred using the FGA -58G>A and FGG 1299 +79T>C SNPs, the most frequent haplotype, FGG-FGA*1 (prevalence 46.6%), was associated with increased risk of MI (OR 1.51; 95%CI 1.18, 1.93), whereas the least frequent haplotype, FGG-FGA*4 (11.8%), was associated with lower risk of MI (OR 0.79 95%CI 0.64, 0.98). In conclusion, fibrinogen haplotypes, but not SNPs in isolation, are associated with variation in risk of MI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735812     DOI: 10.1160/TH04-10-0698

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Relationships of plasma factor VIIa-antithrombin complexes to manifest and future cardiovascular disease.

Authors:  Angela Silveira; Daniela Scanavini; Susanna Boquist; Carl-Göran Ericsson; Mai-Lis Hellénius; Karin Leander; Ulf de Faire; John Ohrvik; Barry Woodhams; James H Morrissey; Anders Hamsten
Journal:  Thromb Res       Date:  2011-09-16       Impact factor: 3.944

2.  Fibrinogen beta variants confer protection against coronary artery disease in a Greek case-control study.

Authors:  Eirini V Theodoraki; Tiit Nikopensius; Julia Suhorutsenko; Vassileios Peppes; Panagiota Fili; Genovefa Kolovou; Vassileios Papamikos; Dimitrios Richter; Nikolaos Zakopoulos; Kaarel Krjutskov; Andres Metspalu; George V Dedoussis
Journal:  BMC Med Genet       Date:  2010-02-18       Impact factor: 2.103

3.  Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors.

Authors:  Stefano Lancellotti; Sergio Rutella; Vincenzo De Filippis; Nicola Pozzi; Bianca Rocca; Raimondo De Cristofaro
Journal:  J Biol Chem       Date:  2008-09-08       Impact factor: 5.157

Review 4.  Molecular genetics of atherosclerosis.

Authors:  Himadri Roy; Shalini Bhardwaj; Seppo Yla-Herttuala
Journal:  Hum Genet       Date:  2009-03-20       Impact factor: 4.132

5.  A genetic instrument for Mendelian randomization of fibrinogen.

Authors:  Gie Ken-Dror; Steve E Humphries; Meena Kumari; Mika Kivimaki; Fotios Drenos
Journal:  Eur J Epidemiol       Date:  2012-03-03       Impact factor: 8.082

6.  Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.

Authors:  Yan Q Chen; Thomas G Pottanat; Robert W Siegel; Mariam Ehsani; Yue-Wei Qian; Eugene Y Zhen; Ajit Regmi; William C Roell; Haihong Guo; M Jane Luo; Ruth E Gimeno; Ferdinand Van't Hooft; Robert J Konrad
Journal:  J Lipid Res       Date:  2020-06-02       Impact factor: 5.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.